ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Cardiovascular Pharmacology and Drug Discovery
Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Ying Lan
Die Hu
Shijing Huang
Min Xu
Qin He
Department of Pharmacy, Chengdu Third People's Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Background: This study aimed to utilize the FDA Adverse Event Reporting System (FAERS) database to systematically investigate the relationship between compound inhaled long-acting bronchodilators for inhalation (ILABs) and cardiovascular adverse events. Methods:We conducted a pharmacovigilance analysis using cardiac adverse event (CAE) reports submitted to FAERS between January 2014 and September 30, 2024. We compared the cardiac toxicity signal intensity of various compound ILABs using the proportional imbalance measurement method. Additionally, we performed subgroup analyses considering factors such as composition, onset time, mortality outcome case information, and concomitant adverse events. Results: Our study comprised 3120 reports on the use of compound ILABs, involving 653 CAEs (454 reports). The most prevalent CAEs observed were atrial fibrillation (14.93%), myocardial infarction (14.37%), cardiac failure congestive (10.96%), cardiac disorder (8.70%), and cardiogenic shock (8.13%). Approximately 20% of CAEs occurred on day 0, and roughly 50% occurred within 90 days. The proportion of CAE reports was similar for triple inhalation formulations and double bronchodilators. But the number of adverse events such as congestive cardiac failure, coronary artery disease, and ventricular extrasystoles associated with triple inhaled formulations was significantly higher than that with dual bronchodilators, with no such reports for the latter. 84.58% of CAE cases were linked to other adverse events. Conclusion: Compound ILABs had significant CAE risk signals, especially those of atrial fibrillation, myocardial infarction and heart failure, and the risk signal was stronger in the early stage of drug treatment. Except for a few individual adverse events, the overall CAE risk signal associated with triple inhaled agents (mainly Fluticasone/umeclidinium/vilanterol) was comparable to that of dual bronchodilators.
Summary
Keywords
Adverse cardiac events, FAERS, LABA, LAMA, long-acting anticholinergic drugs, long-acting beta 2 receptor agonists, pharmacovigilance analysis
Received
01 October 2025
Accepted
29 January 2026
Copyright
© 2026 Lan, Hu, Huang, Xu and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ying Lan
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.